Actinic Keratosis Treatment Market Analysis

Actinic Keratosis Treatment Market Analysis

To get key market trends

  Download Free Sample

By therapy, the actinic keratosis treatment market is classified into photodynamic therapy, surgery and topical medications. The topical medications segment accounted over 49% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Topical medications offer the ability to treat multiple AK lesions simultaneously, making them suitable for widespread or field treatment. Topical medications such as 5-fluorouracil (5-FU), imiquimod are applied directly to the affected areas of the skin, offering targeted therapy. Also, topical treatments are non-invasive and generally most preferred, as they offer convenience and minimal disruption to patients' daily lives.
 

Based on drug class, the market is segmented into NSAIDs, nucleoside metabolic inhibitor, immune response modifiers and photoenhancers. The nucleoside metabolic inhibitor is expected to register USD 3.1 billion in 2032. High segmental development is owing to the convenience of topical application that allows targeted delivery, minimizing systemic exposure to bloodstream and avoid potential side effects. Nucleoside metabolic inhibitor specifically target AK cell growth and proliferation by inhibiting nucleoside processes, leading to lesion regression. Also, clinical studies demonstrate their efficacy in reducing AK lesions, making them a beneficial option for managing actinic keratosis.
 

Actinic keratosis treatment market by end-use is market is divided into hospitals & oncology centers, dermatology clinics, homecare and others. The hospitals & oncology centers accounted for significant market proportion in 2022 and is expected to grow at 5.7% throughout the forecast period. Hospitals & oncology centers offer a wide range of treatment options for actinic keratosis including surgical interventions, cryotherapy, topical medications, photodynamic therapy among others.
 

Also, availability of multiple treatment alternatives allows healthcare providers to opt for most appropriate, suitable approach based on factors such as lesion characteristics, patient preferences and medical considerations. Furthermore, availability of skilled healthcare professionals, advanced healthcare infrastructure among others is projected to boost the market revenue.
 

North America actinic keratosis treatment market accounted for 41.6% business share in 2022 and is anticipated to grow at considerable progress rate during the forecast timeframe. Increasing prevalence of actinic keratosis coupled with well-established healthcare infrastructure is expected to boost the actinic keratosis treatment in the North America region. Furthermore, growing awareness pertaining to various risks associated with sun exposure and regular skin examinations will significantly proliferate the market growth. Additionally, presence of key market players, introduction of innovative therapies and favorable reimbursement policies and insurance coverage for AK treatments in North America region is estimated to spur the market expansion.